Haleon plc American Current Report (Foreign Issuer)

Haleon plc announced the purchase and cancellation of 1,590,000 ordinary shares under the second tranche of its share buyback programme announced 31 July 2025.

Accepted by SEC EDGAR 09/10/2025 - 07:37 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Haleon plc announced the purchase and cancellation of 1,590,000 ordinary shares under the second tranche of its share buyback programme announced 31 July 2025. Following settlement, the company's registered share capital is 8,952,824,051 ordinary shares of £0.01 each, with 1,580,205 held as treasury shares, leaving 8,951,243,846 ordinary shares with voting rights. The announcement directs readers to a full trade breakdown under the Market Abuse Regulation and notes the notice does not constitute an offer for securities. Contact and investor website information are provided.

Insights

Financial Analyst

TL;DR: A small tranche of the announced buyback was executed, slightly reducing shares outstanding and updating voting share count.

The executed purchase of 1,590,000 shares is a routine buyback execution under an existing programme. The updated share and voting counts are useful for ownership threshold calculations under disclosure rules. As a proportion of total registered shares (~8.95 billion), the tranche is immaterial to per-share metrics but maintains the company’s stated capital management activity.

Corporate Governance Expert

TL;DR: Corporate action complies with disclosure standards and provides required voting-share figures for regulatory thresholds.

The notice follows Market Abuse Regulation disclosure requirements by providing a trade breakdown link and updating registered and voting shares. This transparency helps shareholders and regulators monitor changes in ownership and filing obligations. There is no indication of governance or regulatory concerns in this disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	10 September 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

10 September 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 1,590,000 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	09 September 2025	09 September 2025	09 September 2025
Number of Shares purchased:	1,590,000	-	-
Highest price paid per Share (p):	362.1000	-	-
Lowest price paid per Share (p):	359.4000	-	-
Volume weighted average price paid per Share (p):	360.9292	-	-

Following the settlement of the above, the Company's registered share capital is 8,952,824,051 ordinary shares of £0.01 each, of which 1,580,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,951,243,846 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/6770Y_1-2025-9-9.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: September 10, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary